Immune duration of a recombinant PRRSV vaccine expressing E2 of CSFV |
| |
| Affiliation: | 1. Department of Swine Infectious Diseases, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, PR China;2. Jiangsu Co-Innovation Center for the Prevention and Control of Important Animal Infectious Disease and Zoonosis, Yangzhou University, Yangzhou 225009, PR China;1. Department of Anatomy and Comparative Pathology, Faculty of Veterinary Medicine, University of Córdoba, 14014, Córdoba, Spain;2. Department of Anatomy and Comparative Pathology, Faculty of Veterinary Medicine, University of Murcia, 30100, Murcia, Spain;1. Department of Clinical Laboratory Science, Catholic University of Pusan, Busan, 48513, Republic of Korea;2. Department of Clinical Laboratory Science, College of Medical Sciences, Daegu Haany University, Daegu, 38610, Republic of Korea;3. Libentech Co. LTD, C-722 Daedeok BIZ Center, Techno 4-ro, 17 Yuseong-gu, Daejeon, 34013, Republic of Korea;1. Faculty of Veterinary Science, Chulalongkorn University, Pathumwan, Bangkok 10330, Thailand;2. Inter-department of Medical Microbiology, Graduate School, Chulalongkorn University, Pathumwan, Bangkok 10330, Thailand;3. Thai–Denmark Swine Breeder Public Company Limited, Bang-na, Bangkok 10260, Thailand;4. Center of Excellence in Emerging Infectious Diseases in Animals, Chulalongkorn University (CU-EIDAs), Pathumwan, Bangkok 10330, Thailand |
| |
| Abstract: | Classical swine fever virus (CSFV) and Porcine reproductive and respiratory syndrome virus (PRRSV) are both important pathogens which seriously harm the economic swine industry worldwide. We have previously demonstrated that rPRRSV-E2 is a promising live, virus-vectored vaccine that provides 100% protection against highly pathogenic PRRSV (HP-PRRSV) and CSFV. Here, we evaluated the duration of immunity (DOI) of the vaccine strain, rPRRSV-E2. Vaccine or cell culture medium was administered to piglets at 4 weeks of age. All immunized piglets developed high levels of antibodies, which could maintain for up to 23 weeks, against PRRSV and CSFV. All immunized pigs were well protected from the challenge of HP-PRRSV or CSFV at 20 weeks and 24 weeks post vaccination. The vaccine protection rate was still 100% at 24 weeks after immunization. The immune efficacy results showed that the immune duration of rPRRSV-E2 could be up to 5 months. |
| |
| Keywords: | rPRRSV-E2 Duration of immunity Lung lesion Viral load |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
